AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31444999
Drug: Ponatinib 45
RxNorm normalized name: PONATinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 45 mg daily
Trial: 30196134
Drug: Dose and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose and fractionation schedule
Trial: 22424025
Drug: Pravastatin (concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (concomitant treatment)
Trial: 17499999
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 5 mg kg(‐1) after induction of anaesthesia
Trial: 15020614
Drug: Fotemustine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fotemustine 100 mg/m2 weekly for 3 weeks
Trial: 15020614
Drug: DTIC 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC 250 mg/m2/d for 5 consecutive days every 4 weeks
Trial: 10075217
Drug: Serologic screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serologic screening and treatment of syphilis
Trial: 10075217
Drug: Diagnosis and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis and treatment of tuberculosis
Trial: 2650698
Drug: Eating fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eating fish once or twice a week
Trial: 25939436
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone for 21 days in addition to conventional heart failure medication
Trial: 23435927
Drug: IncobotulinumtoxinA (Xeomin(®)),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA (Xeomin(®)), ≤ 50 U per eye, flexible doses, flexible injection intervals (minimum of 6 weeks)
Trial: 17190733
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist (Ca-A)
Trial: 9646426
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 3 g
Trial: 3414406
Drug: Amiloride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (5 mg) and hydrochlorothiazide (50 mg) (Moduretic)
Trial: 31922432
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone (0.2 mg/kg)
Trial: 31922432
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine (1 mg/kg)
Trial: 31922432
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone (0.2 mg/kg) and IV lidocaine (1 mg/kg)
Trial: 31233407
Drug: Fentanyl (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (10 μg/kg intravenously)
Trial: 26281053
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (1 mg twice daily) via transnasal nebulization for one week
Trial: 26281053
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (24 mg QD)
Trial: 23374898
Drug: Rosuvastatin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 2.5 mg/day combined with Ezetimibe 10 mg/day (R2.5/E10)
Trial: 21474637
Drug: 8-week multidisciplinary
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week multidisciplinary group therapy program consisting of physical exercise and educational program
Trial: 18061276
Drug: Pharmacotherapy (PhT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (PhT)
Trial: 16390499
Drug: Testoderm TTS
RxNorm normalized name: Testosterone 5 MG/24 HR Transdermal Patch, Extended Release [TESTODERM TTS]
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testoderm TTS body patch (5 mg/day, n = 20)
Trial: 16390499
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (n = 19)
Trial: 16390499
Drug: Testoderm TTS
RxNorm normalized name: Testosterone 5 MG/24 HR Transdermal Patch, Extended Release [TESTODERM TTS]
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testoderm TTS body patch (5 mg/day, n = 20) and Placebo patch (n = 19)
Trial: 14606111
Drug: Fluconazole (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (low dosage) prevention group
Trial: 10929446
Drug: 1 microgram
RxNorm normalized name: Alfacalcidol 1 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microgram alfacalcidol plus 5000 mg calcium (group A)
Trial: 10929446
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU vitamin D plus 500 mg calcium (group B)
Trial: 1563531
Drug: tolrestat 200
RxNorm normalized name: tolrestat 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolrestat 200 mg once daily for 6 months
Trial: 4003919
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (theophylline + salbutamol)
Trial: 27565426
Drug: Antrodia cinnamomea
RxNorm normalized name: Antrodia cinnamomea fruiting body
DrugBank: Taiwanofungus camphoratus fruiting body (DB19272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antrodia cinnamomea (AC) 20 ml twice daily for 30 days
Trial: 25438877
Drug: Financial reward
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Financial reward for each accepted antipsychotic medication depot (M4M)
Trial: 25438877
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual without financial rewards
Trial: 11809987
Drug: Nottingham Extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nottingham Extended Activities of Daily Living index (NEADL)
Trial: 10609815
Drug: Diclofenac SR
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac SR 75 mg twice daily
Trial: 29446445
Drug: Lenograstim 5
RxNorm normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenograstim 5 micro g/kg
Trial: 29446445
Drug: Biosimilar filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Biosimilar filgrastim 10 micro g/kg
Trial: 27098429
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with BCNU (or busulfan) and thiotepa followed by autologous stem cell transplantation (HCT‐ASCT)
Trial: 27098429
Drug: Conventional‐dose immuno
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional‐dose immuno chemotherapy with rituximab 375 mg/m(2) (d0), dexamethasone 40 mg/d (d1‐3), etoposide 100 mg/m(2)/d (d1‐3), ifosfamide 1500 mg/m(2)/d (d1‐3) and carboplatin 300 mg/m(2) (d1) (R‐DeVIC)
Trial: 24465425
Drug: Progesterone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (300 mg daily)
Trial: 16107306
Drug: aceclofenac-loaded soft
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aceclofenac-loaded soft capsule (100mg)
Trial: 16107306
Drug: conventional aceclofenac
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conventional aceclofenac tablet (100mg)
Trial: 7003573
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release papaverine preparation
Trial: 25885258
Drug: Wrist acceleration
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wrist acceleration measurement pre- and post-treatment
Trial: 24052565
Drug: 2g pralidoxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g pralidoxime over 20 min, followed by an infusion of 0.5 g/h
Trial: 20406523
Drug: Waiting list/delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list/delayed treatment control (WL/DTC)
Trial: 19734776
Drug: Long-term rhGH
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term rhGH at 0.05, 0.1, or 0.2 mg/kg/d
Trial: 19734776
Drug: Long-term rhGH
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term rhGH at 0.2 mg/kg/d
Trial: 19734776
Drug: Long-term rhGH
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term rhGH at 0.1 mg/kg/d
Trial: 19734776
Drug: Long-term rhGH
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term rhGH at 0.1 and 0.2 mg/kg/d
Trial: 8880048
Drug: tramadol controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tramadol controlled release 150 mg (TCR150)
Trial: 8880048
Drug: tramadol controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tramadol controlled release 100 mg (TCR100)
Trial: 8880048
Drug: tramadol standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tramadol standard formulation (T100)
Trial: 2051734
Drug: Lovastatin (1st
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (1st month 20 mg; 2nd and 3rd months 40 mg day‐1)
Trial: 2051734
Drug: Simvastatin (1st
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (1st month 10 mg; 2nd month 20 mg; 3rd month 40 mg day‐1)
Trial: 31495201
Drug: BL-8040 +
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL-8040 + G-CSF
Trial: 31495201
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + G-CSF
Trial: 22349746
Drug: IV saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline infusion 1.5 mL/kg
Trial: 15960429
Drug: 0.4 g
RxNorm normalized name: psyllium 0.4 GM Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g alcohol/kg body weight (females: 10% less)
Trial: 15960429
Drug: 0.7 g
RxNorm normalized name: Bioflavonoid 700 MG/0.7 GM Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 g alcohol/kg body weight (females: 10% less)
Trial: 28972192
Drug: Tadalafil 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 0.3 mg·kg‐1·d‐1
Trial: 28972192
Drug: Tadalafil 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 0.6 mg·kg‐1·d‐1
Trial: 28972192
Drug: Tadalafil (low-dose)
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil (low-dose)
Trial: 28972192
Drug: Tadalafil (high-dose)
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil (high-dose)
Trial: 26939334
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection at Zusanli (ST 36) combined with electroacupuncture (EA) at Hegu (LI 4) and Sanyinjiao (SP 6)
Trial: 26939334
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection and EA
Trial: 22068465
Drug: Natural interferon
RxNorm normalized name: interferon beta natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural interferon α (3 million to 6 million units) administered intramuscularly 3 times a week for 1 year
Trial: 17583373
Drug: Prednisolone plus
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone plus intravenous cyclophosphamide pulse therapy (P/PC)
Trial: 15024666
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (VC) - 200 mg of ascorbic acid twice a day for 14 days prior to exercise and for 3 days after exercise
Trial: 15024666
Drug: Placebo (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P) - identical capsules containing 200 mg lactose
Trial: 9688064
Drug: New 50
RxNorm normalized name: TITANIUM DIOXIDE 50 mg in 1 mL / ZINC OXIDE 150 mg in 1 mL TOPICAL LOTION [La Roche Posay New 50 Body and Face SPF 50 Mineral Anthelios Gentle 100 percent mineral UV filters Soft finish with Cell Ox Shield]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New 50 mg tablet formulation
Trial: 9688064
Drug: Old 50
RxNorm normalized name: Pro-Tec Gold 50 MG/ML Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Old 50 mg tablet formulation
Trial: 9688064
Drug: Suspension containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension containing 50 mg/ml of primidone
Trial: 9688064
Drug: New 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New 250 mg tablet formulation
Trial: 9688064
Drug: Old 250
RxNorm normalized name: OLDENLANDIA DIFFUSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Old 250 mg tablet formulation (two lots)
Trial: 9688064
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg tablet from a second manufacturer
Trial: 2510223
Drug: Midazolam 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.03 mg/kg i.v.
Trial: 2510223
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 ml 0.9% NaCl)
Trial: 355026
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (CDCA) 375 mg/day
Trial: 355026
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (CDCA) 750 mg/day
Trial: 355026
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (CDCA) 1,500 mg/day
Trial: 355026
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (CDCA) 3,000 mg/day
Trial: 355026
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (CDCA) 1,500 mg/day or 17‐24 mg/kg body weight
Trial: 31944270
Drug: Iontophoretic delivery
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoretic delivery of methotrexate, once weekly for 6 sittings.
Trial: 31944270
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% ointment, twice daily for 6 weeks.
Trial: 31240472
Drug: Plitidepsin 5
RxNorm normalized name: Plitidepsine
DrugBank: Plitidepsin (DB04977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plitidepsin 5 mg/m2 on D1 and D15 plus Dexamethasone 40 mg on D1, D8, D15, and D22 (arm A)
Trial: 31240472
Drug: Dexamethasone 40
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 40 mg on D1, D8, D15, and D22 (arm B)
Trial: 26228390
Drug: Telehealth program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth program (MASTERY©) using a mobile application (Breathe-easy©) and a Bluetooth-enabled device (COPD-6®) for self-monitoring of lung function (FEV1, FEV6) twice daily, recording asthma symptoms and medication usage weekly, and a written asthma action plan (WAAP)
Trial: 17693902
Drug: Intranasal E2/NET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal E2/NET 175 microg/275 mug
Trial: 17693902
Drug: Oral E2/NET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2/NET acetate 1 mg/0.5 mg
Trial: 17297830
Drug: Propofol (0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.45 mg x kg(‐1))
Trial: 17297830
Drug: Ketamine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine plus Propofol (0.45 mg x kg(‐1) of propofol plus 0.25 mg x kg(‐1) of ketamine)
Trial: 10625080
Drug: Indomethacin (0.20‐0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.20‐0.25 mg/kg, 12 hourly)
Trial: 10625080
Drug: Ibuprofen (5‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (5‐10 mg/kg, 24 hourly)
Trial: 10625080
Drug: Indomethacin (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (after 24-h dose)
Trial: 10625080
Drug: Indomethacin (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (after 48-h dose of saline)
Trial: 10625080
Drug: Ibuprofen (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (after 24-h and 48-h doses)
Trial: 1591054
Drug: Formestane 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formestane 62.5 mg
Trial: 1591054
Drug: Formestane 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formestane 125 mg
Trial: 29879277
Drug: Oral Valproic
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Valproic Acid (VPA) 500 mg to 1000 mg daily for 12 months
Trial: 25015756
Drug: Thrombin-based topical
RxNorm normalized name: thrombin Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin-based topical hemostatic matrix
Trial: 18582257
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate infusion (n = 92)
Trial: 7861597
Drug: Flumazenil (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.25 mg given initially, followed by another 0.25 mg 2 hours later)
Trial: 7861597
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of flumazenil (0.25 mg in 250 ml of lactated Ringer's solution for 2 hours)
Trial: 2618844
Drug: Self-ratings after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-ratings after exposure to drug stimuli
Trial: 21313894
Drug: M 1.0
RxNorm normalized name: Pitavastatin Calcium 1.045mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M 1.0 (lidocaine 5% and midazolam 1 mg)
Trial: 21313894
Drug: M 0.5
RxNorm normalized name: triazolam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M 0.5 (lidocaine 5% and midazolam 0.5 mg)
Trial: 7577198
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with doxorubicin and cisplatin
Trial: 6459839
Drug: L-tryptophan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (5 g po as a single dose)
Trial: 6459839
Drug: L-tryptophan combined
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan combined with nicotinamide (a tryptophan pyrrolase inhibitor) administered for 1-3 weeks
Trial: 25326008
Drug: Dopamine 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine 7 µg/kg/min (Group D)
Trial: 25326008
Drug: Methoxamine 1
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxamine 1 µg/kg/min (Group M1)
Trial: 25326008
Drug: Methoxamine 2
RxNorm normalized name: methoxamine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxamine 2 µg/kg/min (Group M2)
Trial: 25326008
Drug: Methoxamine 3
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxamine 3 µg/kg/min (Group M3)
Trial: 17102802
Drug: Bicalutamide (Casodex)
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide (Casodex) 150 mg plus standard care
Trial: 15831604
Drug: Secondary preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary preventive treatments
Trial: 14601488
Drug: Serum/plasma levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum/plasma levels of insulin (I), insulin‐like growth hormone‐1 (IGF‐1), luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol (E2), and free triiodothyronine (fT3) in AN
Trial: 27939204
Drug: Glycopyrrolate (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (8 μg/kg 8 hourly)
Trial: 10714911
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of estradiol valerate plus 200 mg of enanthate of dihydroandrosterone im monthly (Group A)
Trial: 10714911
Drug: 50 microg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg/day of transdermal 17-b-estradiol continuously (Group E)
Trial: 10714911
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of tibolone every day (Group T)
Trial: 10714911
Drug: Treatment-free control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-free control group (Group C)
Trial: 8176626
Drug: Ticlopidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (200 mg daily)
Trial: 28185784
Drug: Integrated Neurocognitive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Neurocognitive Therapy (INT)
Trial: 21307816
Drug: baclofen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: baclofen (10 mg)